Ajanta Pharma Limited

BSE: 532331 NSE: AJANTPHARM
Ajanta Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1979PLC022059 Incorporated 31 December 1979 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: AJANTPHARM · BSE: 532331 Public Limited Company pharma
Data last updated
Market Cap
₹44,333 Cr
AJANTPHARM · NSE
Share Price
₹3,525.20
-0.64% today
Revenue
₹5,453 Cr
FY 2025-26 · +19.8% YoY
EBITDA
₹1,395 Cr
Margin 25.6%
Net Profit
₹1,129 Cr
FY 2025-26 · +23.2% YoY
P/E (TTM)
39.1x
P/B 9.8x
ROE
25.4%
ROCE 31.8%
Debt / Equity
0.04
Interest cover 1.3x

About Ajanta Pharma Limited

Data last updated: 28 September 2026

Ajanta Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 31 December 1979, the company has been in operation for over 47 years.

Registered with ROC Mumbai under CIN L24230MH1979PLC022059. Listed on BSE: 532331 and NSE: AJANTPHARM.

Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹24.99 Cr. Formerly known as Ajanta Pharma Private Limited. It is led by directors including Madhusudan Bhagwandas Agrawal and Rajesh Mannalal Agrawal.

Last AGM: 17 July 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹5,452.86 Cr, a growth of 17.31% compared to the previous year. The net worth stands at ₹4,527.09 Cr (up 19.44% YoY). Total assets are valued at ₹4,841.9 Cr (up 23.49% YoY).

The company has a workforce of approximately 7,869 employees as per the latest available data.

The company is associated with 2 brands - Resinno, Ajanta Pharma. As per MCA filings, the company has open charges of ₹65 Cr and satisfied charges of ₹548.84 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ajantapharma.com.

Company Details of Ajanta Pharma Limited
CIN L24230MH1979PLC022059
Registration Number 022059
Incorporation Date 31 December 1979
ROC Mumbai
Listing Status Listed (BSE: 532331, NSE: AJANTPHARM)
Company Status Active
Date of Last AGM 17 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Yogesh Mannalal Agrawal Managing Director Madhusudan Bhagwandas Agrawal Whole-Time Director Rajesh Mannalal Agrawal Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    ajantapharma.com
  • Social Media
  • Registered Address
    Ajanta Tower 54 – A M Vasanji Road, Chakala Andheri (E), Mumbai, Maharashtra, India – 400093
  • Industry
    Pharma, Drug Formulation & Development
Company report
Ajanta Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Ajanta Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Ajanta Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Ajanta Pharma Limited

Ajanta Pharma Limited operates two associated brands: Resinno and Ajanta Pharma. These brands represent Ajanta Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Resinno
Serves as a CDMO specializing in the manufacturing of active pharmaceutical ingredients. resinnobiotech.com
Ajanta Pharma
Generic pharmaceutical products are manufactured across multiple therapeutic segments. ajantapharma.com

Competitors & Alternatives of Ajanta Pharma Limited

Brands and companies operating in the same space as Ajanta Pharma Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Ajanta Pharma Limited

Ajanta Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Ajanta Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Ajanta Pharma Limited

Ajanta Pharma Limited is audited by BSR & Co. LLP for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
BSR & Co. LLP Locked Locked Locked
Premium access

Complete auditor history for Ajanta Pharma Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Ajanta Pharma Limited

Ajanta Pharma Limited is currently managed by 8 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Madhusudan Bhagwandas Agrawal
Also directs: Inspira Realty Llp, Ir Jpv Realty Llp, Inspira Estate Llp and 5 more
Whole-Time Director 31 Dec 1979 46 Years 8 Months Current
Rajesh Mannalal Agrawal
Also directs: Gabs Investments Private Limited, Riteaid Enterprises Llp, Rivea Foundation
Whole-Time Director 30 Apr 2013 13 Years 4 Months Current
Mannalal Bhagwandas Agrawal Director 31 Dec 1979 46 Years 8 Months Current
Yogesh Mannalal Agrawal
Also directs: Valenta Enterprises Llp, Averon Private Limited, Gabs Investments Private Limited
Managing Director 01 Apr 2008 18 Years 5 Months Current
David Paul Rasquinha
Also directs: Ion Exchange (India) Limited, Unity Small Finance Bank Limited, Hsbc Trustees (India) Private Limited and 2 more
Director 02 May 2024 2 Years 4 Months Current
Medha Vinay Joshi Director 02 May 2024 2 Years 4 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Ajanta Pharma Limited FY 2025-26 filings available

Ajanta Pharma Limited reported revenue of ₹5,452.86 Cr (up 17.31% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹5,453 Cr
+17.3% YoY
EBITDA
₹1,395 Cr
+10.7% YoY
Profit After Tax
₹1,129 Cr
+23.2% YoY
Net Worth
₹4,527 Cr
+19.4% YoY
Total Assets
₹4,842 Cr
+23.5% YoY
Total Debt
₹260 Cr
+448.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,4534,6484,2093,7433,3412,8902,588
Revenue growth+19.8%+11.6%+2.6%+22.7%+27.5%-0.9%+28.2%
EBITDA1,3951,2601,172783929999679
EBITDA margin+25.6%+27.1%+27.9%+20.9%+27.8%+34.6%+26.3%
Profit before tax1,3781,1891,114745909900664
Net profit1,129916808594713651471
Net profit margin+20.7%+19.7%+19.2%+15.9%+21.4%+22.5%+18.2%
EPS (₹)84.2473.4364.6046.5483.0175.2053.33
Balance sheet
Total assets4,8423,9213,6463,4513,3133,0502,694
Net worth4,5273,7903,5673,3883,2642,9962,599
Total debt26047.4235.2835.6325.0331.3674.96
Cash & bank105176131331212210205
Net working capital1,9811,4211,5171,1941,5021,2151,031
Cash flow
Cash from operations5291,157785792562576457
Cash from investing(429)(377)65.39(560)(74.10)(282)(224)
Cash from financing(168)(733)(1,051)(108)(460)(318)(129)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,6261,4221,3751,3541,3031,1701,1461,187
Revenue growth (YoY)+24.8%+21.5%+20.0%+14.1%+13.8%+11.0%+3.7%+15.4%
Other income70.9061.4324.9759.3426.3318.1130.4419.48
EBITDA424333382328351297321311
EBITDA margin+26.1%+23.5%+27.8%+24.2%+27.0%+25.4%+28.0%+26.2%
Depreciation44.5045.3743.5142.9741.2939.7835.9734.39
Interest3.182.365.103.395.266.077.916.02
Profit before tax447347359341331269307290
Tax11380.4184.8380.6275.7944.1574.5173.76
Net profit334267274260255225233216
EPS (₹)26.7221.3421.9120.8220.4318.0018.5917.26
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,8464,3223,9713,4113,1412,7192,196
Revenue growth+17.0%+9.3%+5.2%+20.6%+24.9%+8.0%+29.1%
EBITDA1,1981,2051,119699891917529
EBITDA margin+24.7%+27.9%+28.2%+20.5%+28.4%+33.7%+24.1%
Profit before tax1,2311,1801,097700901902613
Net profit942906796546720673444
Net profit margin+19.4%+21.0%+20.1%+16.0%+22.9%+24.8%+20.2%
EPS (₹)75.5373.1563.8944.2283.8577.7050.30
Balance sheet
Total assets4,3133,7403,4873,3073,2132,9332,505
Net worth4,2243,6253,4143,2463,1692,8852,461
Total debt34.6931.1730.5232.9020.4925.9123.49
Cash & bank90.5549.7263.0627014515287.85
Net working capital1,6731,4331,4901,1411,4701,191885
Cash flow
Cash from operations8041,054735736542467301
Cash from investing(400)(350)105(501)(66.04)(163)(116)
Cash from financing(360)(716)(1,048)(105)(457)(269)(134)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,4891,2111,2071,2201,2091,0141,1021,129
Revenue growth (YoY)+23.2%+19.4%+9.5%+8.1%+12.2%+9.5%+1.5%+19.4%
Other income70.8262.9825.7675.0340.6317.9333.2340.34
Total expenses1,092972866931879764766826
EBITDA397238341290329250336303
EBITDA margin+26.6%+19.7%+28.3%+23.7%+27.3%+24.6%+30.5%+26.8%
Depreciation43.3144.1642.3841.9240.3138.7634.9333.32
Interest0.76(0.74)1.870.730.730.672.480.73
Profit before tax423258322322329228332309
Tax10860.3377.4272.4474.0234.7279.7074.22

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,6261,4221,3751,3541,3031,1701,1461,187
Revenue growth (YoY)+24.8%+21.5%+20.0%+14.1%+13.8%+11.0%+3.7%+15.4%
Other income70.9061.4324.9759.3426.3318.1130.4419.48
EBITDA424333382328351297321311
EBITDA margin+26.1%+23.5%+27.8%+24.2%+27.0%+25.4%+28.0%+26.2%
Depreciation44.5045.3743.5142.9741.2939.7835.9734.39
Interest3.182.365.103.395.266.077.916.02
Profit before tax447347359341331269307290
Tax11380.4184.8380.6275.7944.1574.5173.76
Net profit334267274260255225233216
EPS (₹)26.7221.3421.9120.8220.4318.0018.5917.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,4534,6484,2093,7433,3412,8902,588
Revenue growth+19.8%+11.6%+2.6%+22.7%+27.5%-0.9%+28.2%
Other income17294.5084.6098.6411625.9892.19
Total expenses4,0583,3893,0372,9592,4121,8911,908
Employee cost1,2911,090900785646548486
EBITDA1,3951,2601,172783929999679
EBITDA margin+25.6%+27.1%+27.9%+20.9%+27.8%+34.6%+26.3%
Depreciation17314413513112511695.72
Interest16.1120.737.215.8410.208.2711.91
Profit before tax1,3781,1891,114745909900664
Tax322269298157197246196
Net profit1,129916808594713651471
Net profit margin+20.7%+19.7%+19.2%+15.9%+21.4%+22.5%+18.2%
EPS (₹)84.2473.4364.6046.5483.0175.2053.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.0725.0725.2725.2717.1717.3917.54
Reserves & surplus4,5023,7653,5423,3633,2472,9782,581
Shareholders' funds (net worth)4,5273,7903,5673,3883,2642,9962,599
Minority interest0.000.000.000.000.000.000.00
Secured loans2122.591.491.431.911.6945.68
Unsecured loans48.1844.8333.7934.2023.1229.6729.28
Total debt26047.4235.2835.6325.0331.3674.96
Total liabilities4,8423,9213,6463,4513,3133,0502,694
Assets
Gross block3,0462,8012,3892,2832,2182,1411,975
Net block1,8671,7621,4791,4961,5121,5411,472
Capital work in progress258176256209153108132
Investments58846434953514717679.42
Inventories939904828816791766496
Sundry debtors1,8541,1831,2471,0571,020738775
Cash & bank balances105176131331212210205
Loans & advances27814119512012013798.34
Total current assets3,1762,4042,4012,3242,1431,8521,575
Total current liabilities1,1959838841,130641637544
Net working capital1,9811,4211,5171,1941,5021,2151,031
Total assets4,8423,9213,6463,4513,3133,0502,694
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash17512933020617820295.16
Net cash from operating activities5291,157785792562576457
Net cash from investing activities(429)(377)65.39(560)(74.10)(282)(224)
Net cash from financing activities(168)(733)(1,051)(108)(460)(318)(129)
Net change in cash(67.65)47.30(201)12427.90(24.36)104
Closing cash105176131331212210205
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.3%+10.4%+12.5%+12.0%+15.6%+11.7%+25.9%
EBITDA growth+10.7%+7.5%+49.6%-15.7%-6.9%+47.0%+20.0%
PBT growth+15.9%+6.8%+49.5%-18.1%+1.0%+35.6%+29.1%
Net income growth+23.2%+13.4%+36.0%-16.7%+9.5%+38.4%+21.5%
Revenue CAGR (3Y)+13.4%+11.6%+13.4%+13.1%+17.6%+10.8%+9.3%
EBITDA CAGR (3Y)+21.2%+10.7%+5.5%+4.9%+17.9%+14.9%-0.4%
Profitability & leverage
Net income margin+19.4%+19.8%+19.4%+15.7%+21.3%+22.6%+18.1%
Return on capital employed+31.8%+32.0%+31.6%+22.2%+28.9%+31.6%+27.1%
Return on net worth+25.4%+25.0%+23.5%+17.7%+22.8%+23.4%+19.3%
Debt / equity0.040.010.010.010.010.020.02
Long-term debt / equity0.010.010.010.010.010.010.00
Interest cover1.321.860.700.901.270.942.04
Efficiency & per share
Fixed asset turnover1.871.791.801.661.531.401.45
Inventory turnover5.925.375.124.664.294.585.56
Debtors turnover3.593.833.653.603.803.824.19
EPS (₹)84.2473.4364.6046.5483.0175.2053.33
Dividend per share (₹)28.0028.0051.007.009.509.5013.00
Book value per share (₹)361.16302.38282.34268.14380.24344.52296.34
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,4891,2111,2071,2201,2091,0141,1021,129
Revenue growth (YoY)+23.2%+19.4%+9.5%+8.1%+12.2%+9.5%+1.5%+19.4%
Other income70.8262.9825.7675.0340.6317.9333.2340.34
Total expenses1,092972866931879764766826
EBITDA397238341290329250336303
EBITDA margin+26.6%+19.7%+28.3%+23.7%+27.3%+24.6%+30.5%+26.8%
Depreciation43.3144.1642.3841.9240.3138.7634.9333.32
Interest0.76(0.74)1.870.730.730.672.480.73
Profit before tax423258322322329228332309
Tax10860.3377.4272.4474.0234.7279.7074.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,8464,3223,9713,4113,1412,7192,196
Revenue growth+17.0%+9.3%+5.2%+20.6%+24.9%+8.0%+29.1%
Other income204120116133140104184
Total expenses3,6483,1172,8522,7122,2501,8021,668
Employee cost1,1941,011834720586498438
EBITDA1,1981,2051,119699891917529
EBITDA margin+24.7%+27.9%+28.2%+20.5%+28.4%+33.7%+24.1%
Depreciation16914013212712111191.29
Interest2.594.606.805.239.126.909.10
Profit before tax1,2311,1801,097700901902613
Tax284263290141181226172
Net profit942906796546720673444
Net profit margin+19.4%+21.0%+20.1%+16.0%+22.9%+24.8%+20.2%
EPS (₹)75.5373.1563.8944.2283.8577.7050.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.0725.0725.2725.2717.1717.3917.54
Reserves & surplus4,1983,6003,3883,2213,1522,8682,444
Shareholders' funds (net worth)4,2243,6253,4143,2463,1692,8852,461
Secured loans0.000.000.000.000.000.000.00
Unsecured loans34.6931.1730.5232.9020.4925.9123.49
Total debt34.6931.1730.5232.9020.4925.9123.49
Total liabilities4,3133,7403,4873,3073,2132,9332,505
Assets
Gross block2,9962,7602,3552,2462,1632,0871,927
Net block1,8451,7421,4651,4841,4921,5191,449
Capital work in progress258176256209153108131
Investments60648236755316515785.77
Inventories845739678684635634436
Sundry debtors1,3661,2261,2089781,044782734
Cash & bank balances90.5549.7263.0627014515287.85
Loans & advances25812316311011112989.66
Total current assets2,5592,1372,1122,0411,9351,6971,348
Total current liabilities886704622900466506463
Net working capital1,6731,4331,4901,1411,4701,191885
Total assets4,3133,7403,4873,3073,2132,9332,505
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash48.6061.7826914012084.9530.52
Net cash from operating activities8041,054735736542467301
Net cash from investing activities(400)(350)105(501)(66.04)(163)(116)
Net cash from financing activities(360)(716)(1,048)(105)(457)(269)(134)
Net change in cash44.65(11.51)(207)13019.0035.4150.97
Closing cash90.5549.7263.0627014515287.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.1%+8.8%+16.4%+8.6%+15.5%+23.8%+23.9%
EBITDA growth-0.6%+7.6%+60.1%-21.5%-2.8%+73.4%+9.9%
PBT growth+4.3%+7.6%+56.7%-22.3%-0.2%+47.2%+19.4%
Net income growth+3.9%+13.8%+45.9%-24.2%+7.1%+51.5%+13.3%
Revenue CAGR (3Y)+12.4%+11.2%+13.5%+15.8%+21.0%+14.2%+6.8%
EBITDA CAGR (3Y)+19.7%+10.6%+6.9%+9.8%+22.8%+18.8%-5.9%
Profitability & leverage
Net income margin+19.5%+21.2%+20.3%+16.4%+22.9%+24.9%+20.1%
Return on capital employed+30.6%+32.8%+32.5%+21.6%+29.6%+33.4%+26.7%
Return on net worth+24.1%+26.1%+24.2%+17.4%+23.8%+25.3%+19.2%
Debt / equity0.010.010.010.010.010.010.01
Long-term debt / equity0.010.010.010.010.010.010.00
Interest cover0.250.430.690.911.180.862.08
Efficiency & per share
Fixed asset turnover1.681.691.731.551.481.351.26
Inventory turnover6.126.105.835.174.955.085.17
Debtors turnover3.743.553.633.383.443.593.79
EPS (₹)75.5373.1563.8944.2283.8577.7050.30
Dividend per share (₹)28.0028.0051.007.009.509.5013.00
Book value per share (₹)336.94289.21270.17256.94369.15331.80280.65
Want more history and ratios?
You're viewing the latest exchange-filed financials for Ajanta Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Ajanta Pharma Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 63.50%, foreign institutional investors hold 7.70%, domestic institutional investors hold 21.80%, retail and other public shareholders hold 7.00% of Ajanta Pharma Limited.

Promoters: 63.50%DII (Domestic Institutional): 21.80%FII (Foreign Institutional): 7.70%Retail & Others: 7.00%
Jun 2026
QUARTER
63.50% Promoters
21.80% DII (Domestic Institutional)
7.70% FII (Foreign Institutional)
7.00% Retail & Others
Promoter holding - history
Now 63.50% · Jun 2026High 66.20% · Sep 2025Low 63.50% · Jun 2026
62%63.5%65%66.5%68%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 66.20%Dec 2025: 66.20%Mar 2026: 66.20%Jun 2026: 63.50%66.20%63.50%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters63.50%66.20%66.20%66.20%
Public36.50%33.80%33.80%33.80%

Charges & Borrowings of Ajanta Pharma Limited

Open charges
₹65 Cr
Satisfied charges
₹548.84 Cr
Breakdown by lending institutions
Citi Bank N.A.₹35.00 Cr
Others₹20.00 Cr
Idbi Bank Limited₹10.00 Cr
Latest charge details
DateLenderAmountStatus
25 Jan 2024 Idbi Bank Limited ₹10 Cr Open
11 Feb 2021 Others ₹10 Cr Open
26 Jun 2020 Citi Bank N.A. ₹35 Cr Open
03 Jul 1997 Others ₹10 Cr Open
21 Mar 2013 State Bank of Mauritius Limited ₹55.16 Cr Satisfied

Total charge records: 35 View all charges

Employees and EPFO Compliance at Ajanta Pharma Limited

Ajanta Pharma Limited has a workforce of 7,869 employees as of Sep 23, 2025.

Employee count
7,869
Active EPFO establishments
9
Employee growth
2.85%
Premium access

Employee and EPFO history for Ajanta Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Ajanta Pharma Limited

Premium access

GST registrations and filing compliance for Ajanta Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Ajanta Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Ajanta Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Ajanta Pharma Limited

Premium access

MSME payment history for Ajanta Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Ajanta Pharma Limited

Premium access

Corporate group structure for Ajanta Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Ajanta Pharma Limited

Premium access

MCA filings and documents for Ajanta Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Ajanta Pharma Limited

Activity
17 Jul 2025
Ajanta Pharma Limited last Annual general meeting of members was held on 17 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Ajanta Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
02 May 2024
David Paul Rasquinha was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 4 months.
Directors
02 May 2024
Medha Vinay Joshi was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 4 months.
Directors
02 May 2024
Simi Manohar Lal Thapar was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 4 months.
Directors
02 May 2024
Rajesh Shashikant Dalal was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 4 months.

Recent News on Ajanta Pharma Limited

Frequently Asked Questions about Ajanta Pharma Limited

Ajanta Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 31 December 1979 (47+ years old) and is registered under CIN L24230MH1979PLC022059. Listed on BSE: 532331 and NSE: AJANTPHARM. The company has 7,869 employees.

Ajanta Pharma Limited reported revenue of ₹5,452.86 Cr for FY 2025-26 (up 17.31% YoY) based on consolidated financials.

The current directors of Ajanta Pharma Limited are:

The primary industry of Ajanta Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Ajanta Pharma Limited is listed on both BSE (code: 532331) and NSE (symbol: AJANTPHARM).

Ajanta Pharma Limited can be reached at the registered office: Ajanta Tower 54 – A M Vasanji Road, Chakala Andheri E, Mumbai, Maharashtra, India – 400093, or through the website ajantapharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available